West Pharmaceutical Services Inc. (WST) shares have increased by 32.9% year to date in 2026, significantly outperforming the industry average decline of 30.3% and the S&P 500’s 28.2% gain. This uptick follows a strong first-quarter earnings report, where the company posted revenues of $845 million—up 21% year-over-year—and adjusted earnings per share rose by 47%. Management has raised its full-year guidance, projecting continued growth supported by rising demand in high-value injectable drug components and biologics, particularly for GLP-1 therapies.
Key factors contributing to WST’s performance include a 23% organic growth in high-value product components, driven by increasing adoption of GLP-1 treatments, which accounted for 10% of total sales in the first quarter. Additionally, the company experienced a 26% growth in its biologics segment, significantly bolstered by the global launch of biosimilars and expanding demand for injectable packaging solutions. The recent implementation of Europe’s stringent Annex 1 regulations has also generated a 66% increase in related projects, potentially contributing an additional 200 basis points to 2026 revenues.
Looking ahead, WST’s earnings per share are projected to grow by 18% in 2026 to $8.60 and by 10.5% in 2027 to $9.50. Revenue for 2026 is expected to rise by 8.4% to $3.33 billion, with a further 6.4% growth anticipated in 2027. Despite these positive indicators, potential risks include rising commodity costs and increased competition from firms like Baxter International Inc. and Becton Dickinson and Company, which could impact margins and market dynamics.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
